ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts and presbyopia. The potential impact of this project is enormous. Cataracts are the leading cause of blindness in the world, with the vast majority of people affected – 10.4 million – living in developing countries, where impaired vision can have drastic financial and medical implications. Viewpoint Therapeutics is developing non-surgical therapy that could revolutionize the treatment of visual impairment and blindness.